Author:
León-Cachón Rafael B. R.,Ascacio-Martínez Jorge A.,Gamino-Peña María E.,Cerda-Flores Ricardo M.,Meester Irene,Gallardo-Blanco Hugo L.,Gómez-Silva Magdalena,Piñeyro-Garza Everardo,Barrera-Saldaña Hugo A.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference57 articles.
1. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141–60. doi:
10.2165/00003088-200342130-00005
.
2. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004;14(8):523–5. doi:
00008571-200408000-00005
.
3. Ahmed T, Kollipara S, Gautam A, Gigras R, Kothari M, Saha N, et al. Bioavailability and Interaction Potential of Atorvastatin and Losartan on Coadministration in Healthy Human Subjects. J Bioequivalence Bioavailability. 2009;1(1):018–27. doi:
10.4172/jbb.1000004
.
4. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000;28(11):1369–78.
5. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther. 2010;87(1):65–73. doi:
10.1038/clpt.2009.181
.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献